Current Views on the Role of MicroRNAs in Psychosis

Aoife Kearney, Javier A. Bravo, Timothy G. Dinan

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


The psychotic disorders of schizophrenia and bipolar affective disorder are severe and enduring medical conditions that typically have a natural course spanning many decades, oftentimes punctuated with frequent relapses requiring hospitalization. Current treatment regimens often include antipsychotic medications that target monoamine receptors. While these agents ameliorate symptoms and aid in relapse prevention, they are rarely curative. The clinical phenotype can have variable presentations, and miRNA studies are further adding to the depth of its biological complexity. Such research is providing a more comprehensive understanding of the pathophysiology, with postmortem studies indicating alterations in miR-181b and miR-195 in schizophrenia and miR219 in both schizophrenia and bipolar illness. This chapter looks at limitations in the current gold standard therapeutic options, their biological origins, and the potential role miRNA modulation in psychotic illness could play in future novel treatments.

Original languageEnglish
Title of host publicationMicroRNAs in Medicine
PublisherWiley Blackwell
Number of pages14
ISBN (Electronic)9781118300312
ISBN (Print)9781118300398
StatePublished - 4 Nov 2013
Externally publishedYes


  • Antagomirs
  • Antipsychotics
  • Antipsychotics
  • Bipolar affective disorder
  • Brain derived neurotrophic factor
  • Glutamate
  • MiR-181b
  • MiR-219
  • Monoamines
  • Schizophrenia


Dive into the research topics of 'Current Views on the Role of MicroRNAs in Psychosis'. Together they form a unique fingerprint.

Cite this